drugset / Trial / NCT03281551
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Phase 1
Unknown
50 enrolled
Pinze Lifetechnology Co. Ltd.
Chinese Academy of Sciences · collabNavy General Hospital, Beijing · collab
NaSingle-groupOpen-labelTreatment
Summary
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.
Timeline
- Start
- 2017-10-01
- Primary completion
- 2020-09-01
- Completion
- 2020-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PZ01 | Unknown | — | — |